Kaposi's sarcoma in renal transplant recipients - The impact of proliferation signal inhibitors

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL. 1, 2007, Pages

  Campistol, Josep M ^a   Schena, Francesco P ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b POLICLINICO   (Italy)

Author keywords

Kaposi's sarcoma; Post transplant malignancy; Proliferation signal inhibitors mammalian target of rapamycin inhibitors; Renal transplant recipients

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DOXORUBICIN; EVEROLIMUS; FINGOLIMOD; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VASCULOTROPIN; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PNEUMOCYSTOSIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEINURIA; PRURITUS; RASH; RISK REDUCTION; SKIN DISEASE; TUMOR VASCULARIZATION; DRUG ANTAGONISM; DRUG EFFECT; REVIEW; SIGNAL TRANSDUCTION;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROTEIN KINASES; SARCOMA, KAPOSI; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34250175840     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm089     Document Type: Article

References (17)

1. Tan HH, Goh CL. Viral infections affecting the skin in organ transplant recipients: Epidemiology and current management strategies. Am J Clin Dermatol 2006; 7: 13-29
2. Mendez JC, Paya CV. Kaposi's sarcoma and transplantation. Herpes 2000; 7: 18-23
3. Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869
4. Wang QJ, Jenkins FJ, Jacobson LP et al. Primary human herpes-virus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins. Blood 2001; 97: 2366-2373
5. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323
6. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762
7. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
8. Farge D. Kaposi's sarcoma in organ transplant recipients. The Collaborative Transplantation Research Group of Ile de France. Eur J Med 1993; 2: 339-343
9. Vincent T, Moss K, Colaco, B, Venables PJ. Kaposi's sarcoma in two patients following low-dose corticosteroid treatment for rheumatological disease. Rheumatology (Oxford) 2000; 39: 1294-1296
10. Zmonarski SC, Boratynska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M. Kaposi's sarcoma in renal transplant recipients. Ann Transplant 2005; 10: 59-65
11. Hussein MM, Mooij JM, Roujouleh HM. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead. Nephrol Dial Transplant 2000; 15: 1103-1104
12. Gutiérrez-Dalmau Á, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; 22 [Suppl 1]: I11-i16
13. Gutíerrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 2005; 37: 3836-3838
14. Mohsin N, Budruddin M, Pakkyara A et al. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus. Exp Clin Transplant 2005; 3: 366-369
15. Gonzalez-Lopez MA, Rodrigo E, Gonzalez-Vela MC et al. Posttransplant Kaposi's sarcoma restricted to the site of a previous deep vein thrombosis: Abrupt onset after withdrawal of sirolimus. Dermatology 2006; 213: 30-33
16. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135
17. Sodhi A, Chaisuparat R, Hu J et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10: 133-143